Doctor with Blood Tube

Introducing a non-invasive blood test for advanced liver fibrosis due to NASH

As many as 4 to 6 million people are projected to have advanced fibrosis due to NASH1

By 2030, NASH (non-alcoholic steatohepatitis) is predicted to be the #1 leading indication for liver transplant.1,2 Our Enhanced Liver Fibrosis (ELF™) Test is the first blood test granted De Novo marketing authorization by the FDA for prognosis in advanced fibrosis due to NASH.

Want to know more about our innovations? Join us for the AACC 2021 Virtual Experience.

1

2